Salk Institute for Biological Studies:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Salk Institute for Biological Studies - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9312)・商品コード:DATA904C9312
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:40
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Salk Institute for Biological Studies (Salk) is a research institute that offers biological research programs. The institute’s areas of research comprise aging and regenerative medicine, cancer biology, immune system biology, metabolism and diabetes, neuroscience and neurological disorders, and plant biology. Its research provides development of new therapies and treatments for diseases such as cancer, AIDS, Alzheimer’s disease, cardiovascular disorders, anomalies of brain, birth defects, diabetes and metabolism, gene therapy, plant biology, vision, and williams syndrome, among others. Salk offers education outreach programs that deliver research impact on human health. The institute operates research centers such as Salk Cancer Center, Crick-Jacobs Center, Helmsley Center for Genomic Medicine, Center for the Neurobiology of Vision and Center for Nutritional Genomics, among others. Salk is headquartered in San Diego, California, the US.

Salk Institute for Biological Studies – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Salk Institute Enters into Agreement with Indivumed 10
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 11
Licensing Agreements 12
Metacrine Enters into Licensing Agreement with Salk Institute for Biological Studies 12
StemCell Technologies Enters into Licensing Agreement with Salk Institute for BrainPhys 13
Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 14
Salk Institute for Biological Studies – Key Competitors 15
Salk Institute for Biological Studies – Key Employees 16
Salk Institute for Biological Studies – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Government and Public Interest 18
Oct 02, 2018: Salk’s Janelle Ayres receives nih pioneer award for novel approaches to infectious disease 18
Sep 20, 2018: Decoding the structure of an RNA-based CRISPR system 19
Sep 18, 2018: Tweaking cells’ gatekeepers could lead to new way to fight cancer 20
Sep 13, 2018: Research in yeast leads to serendipitous finding about a central nervous system disorder 21
Sep 05, 2018: The alchemy of healing: Researchers turn open wounds into skin 22
Aug 30, 2018: A master switch controls aggressive breast cancer 23
Aug 23, 2018: Salk’s donors give $48.5 million to support scientific innovation in FY18 25
Aug 21, 2018: Salk Institute receives $2 million for cancer research initiative 26
Jul 11, 2018: Janelle Ayres receives $1 million from W. M. Keck Foundation for infectious disease research 27
Jun 26, 2018: Salk researchers win five competitive grants for cancer research 28
May 18, 2018: Salk Institute receives $1.5 million for Alzheimer’s research from NANOS 30
Mar 14, 2018: CRISPR genetic editing takes another big step forward, targeting RNA 31
Mar 13, 2018: Molecule That Gives Energy-Burning Brown Fat Its Identity Could Lead To Drugs For Obesity 33
Sep 19, 2017: CPRIT awards $34M to UTSW for cancer research recruitment 34
May 30, 2017: Brain’s immune cells linked to Alzheimer’s, Parkinson’s, schizophrenia 36
Feb 14, 2017: Salk scientist awarded inaugural Sjoberg Prize for cancer breakthrough 38
Other Significant Developments 39
Oct 18, 2018: Brain cells called astrocytes have unexpected role in brain plasticity 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Key Facts 2
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Salk Institute for Biological Studies, Deals By Therapy Area, 2012 to YTD 2018 8
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Salk Institute Enters into Agreement with Indivumed 10
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 11
Metacrine Enters into Licensing Agreement with Salk Institute for Biological Studies 12
StemCell Technologies Enters into Licensing Agreement with Salk Institute for BrainPhys 13
Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 14
Salk Institute for Biological Studies, Key Competitors 15
Salk Institute for Biological Studies, Key Employees 16

List of Figures
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Salk Institute for Biological Studies, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Salk Institute for Biological Studies:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9312)販売に関する免責事項を必ずご確認ください。
★調査レポート[Salk Institute for Biological Studies:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆